Recent studies have showed that Tα1 therapy can benefit elderly COVID-19 patients by modulating T lymphocyte responses, specifically by increasing CD4+ and CD8+ T cell populations while preventing excessive activation of CD8+ T cells (Liu et al., 2020; Yu et al., 2020). Here, CD8A is linked to COVID-19.